![](https://cdn.sanity.io/images/0vv8moc6/neurolive/ded5baf26be32ebd28bd0e14d1011d2fae813b65-300x300.png?fit=crop&auto=format)
Investigational PrimeC Improves Complication-Free Survival in PARADIGM Study of ALS
Weeks after NeuroSense announced positive data from the phase 2b PARADIGM trial (NCT05357950), newly announced analyses revealed that treatment with investigational PrimeC resulted in enhanced complication-free survival over placebo in patients with …